Symplmed Pharmaceuticals LLC found an individual investor who has bought into the company's plan of introducing a disruptive sales strategy that incentivizes doctors and patients to use its blood pressure therapies.

The newco, which spun out of Xoma Corp. (NASDAQ:XOMA) this month, will start rolling out its Dyrct Axess marketing platform this quarter using Aceon perindopril as its test case.